2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Ser/Thr Protease

Ser/Thr Protease

Serine proteases; Serine endopeptidases; Threonine proteases

Ser/Thr Protease

Related Products

PDF 0.83 MB

Serine (Ser) proteases catalyse the hydrolysis of specific peptide bonds in their substrates and this activity depends on a set of amino acids in the active site of the enzyme, one of which is always a serine. There are two families especially well studied, the trypsin family and the subtilisin family. Serine proteases play crucial roles in a wide variety of cellular as well as extracellular functions, including the process of blood clotting, protein digestion, cell signaling, inflammation, and protein processing. Threonine (Thr) proteases are a family of proteolytic enzymes harbouring a threonine residue within the active site. The prototype members of this class of enzymes are the catalytic subunits of the proteasome, however the acyltransferases convergently evolved the same active site geometry and mechanism.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99187
    Bococizumab
    		Inhibitor 99.9%
    Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia.
    Bococizumab
  • HY-P2276
    Pep2-8
    		Inhibitor 99.74%
    Pep2-8 is a PCSK9 inhibitor with a binding KD of 0.7 μM and an IC50 of 1.4 μM.
    Pep2-8
  • HY-16735
    Avoralstat
    		Inhibitor ≥98.0%
    Avoralstat (BCX4161), a potent and orally active plasma kallikrein (PKK) inhibitor, is used for hereditary angioedema research.
    Avoralstat
  • HY-111192
    IPR-803
    		Inhibitor ≥98.0%
    IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction (PPI). IPR-803 binds directly to uPAR with sub-micromolar affinity. IPR-803 displays anti-tumor activity.
    IPR-803
  • HY-P9928
    Alirocumab
    		Inhibitor
    Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of PCSK9. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia.
    Alirocumab
  • HY-109127A
    Berotralstat dihydrochloride
    		Inhibitor 98.49%
    Berotralstat dihydrochloride is a low toxicity, effective, highly specific, second-generation, synthetic and orally active plasma kallikrein inhibitor used for the research of hereditary angioedema (HAE) attacks. Berotralstat dihydrochloride works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE.
    Berotralstat dihydrochloride
  • HY-100415
    UKI-1
    		Inhibitor
    UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells.
    UKI-1
  • HY-132830
    Sebetralstat
    		Inhibitor
    Sebetralstat (KVD900) is a plasma kallikrein inhibitor (WO2016083820). Sebetralstat can be used for the research of metabolic diseases.
    Sebetralstat
  • HY-101354
    R-IMPP
    		Inhibitor 98.42%
    R-IMPP (PF-00932239) is an anti-secretagogue of PCSK9 (IC50=4.8 μM), which targets the 80S ribosome to inhibit PCSK9 protein translation.
    R-IMPP
  • HY-111056
    UK122
    		Inhibitor
    UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50>100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion.
    UK122
  • HY-148673
    PCSK9-IN-12
    		99.97%
    PCSK9-IN-12 is a heteroaryl compound. PCSK9-IN-12 has bind affinity for PCSK9 with a Kd value of ＜200 nM. PCSK9-IN-12 can be used for the research of cholesterol metabolism.
    PCSK9-IN-12
  • HY-124379
    TPCK
    		Inhibitor 98.55%
    TPCK (L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK) is a potent serine protease inhibitor that reacts with the retinoblastoma protein (RB)-binding core of HPV-18 E7 protein and abolish its RB-binding capability. TPCK is able to modify E7 protein in live keratinocytes following its addition to the culture medium.
    TPCK
  • HY-129571
    BioE-1115
    		Inhibitor 99.56%
    BioE-1115 is a highly selective and potent PAS kinase (PASK) inhibitor with an IC50 of ~4 nM. BioE-1115 is also a potent casein kinase 2α inhibitor with an IC50 of ~10 μM.
    BioE-1115
  • HY-109127
    Berotralstat
    		Inhibitor 99.70%
    Berotralstat (BCX7353) is a low toxicity, effective, highly specific, second-generation, synthetic and orally active plasma kallikrein inhibitor used for the research of hereditary angioedema (HAE) attacks. Berotralstat works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE.
    Berotralstat
  • HY-152221
    PCSK9-IN-10
    		Inhibitor 98.95%
    PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia.
    PCSK9-IN-10
  • HY-134616
    Ulinastatin
    		Inhibitor
    Ulinastatin (Uristatin) is a trypsin and serine protease inhibitor. Ulinastatin is the main protein binding inhibitor of various trypsin, chymotrypsin, and various pancreatic proteases. Ulinastatin shows neuroprotective, anti-inflammatory, anti-apoptotic, anti-oxidant effects.
    Ulinastatin
  • HY-137456
    Tilpisertib
    		Inhibitor 99.21%
    Tilpisertib (GS-4875) is a serine/threonine kinase inhibitor (WO2017007689).
    Tilpisertib
  • HY-118131
    PKR-IN-C51
    		Inhibitor 99.93%
    PKR-IN-C51(compound 51) is an ATP-competitive double-stranded RNA-activated protein kinase (PKR) inhibitor with an IC50 of 9 μM. PKR-IN-C51 inhibits intracellular PKR activation in a dose-dependent manner in primary mouse macrophages.
    PKR-IN-C51
  • HY-P99110
    Lanadelumab
    		Inhibitor 99.57%
    Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema.
    Lanadelumab
  • HY-139439
    SBI-581
    		98.83%
    SBI-581 is an orally active and potent selective serine-threonine kinase TAO3 inhibitor, with an IC50 of 42 nM. SBI-581 promotes TKS5α accumulation at RAB11-positive vesicles. SBI-581 inhibits invadopodia formation. SBI-581 shows reasonable pharmacokinetics in mice using IP injection. SBI-581 shows antitumor activity. SBI-581 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    SBI-581
Cat. No. Product Name / Synonyms Application Reactivity